glaucoma

This article was originally published on The Fresh Toast and appears here with permission. Marijuana has been shown to help relieve certain types of pain, nausea, and vomiting, as well as some mental health disorders. But what about glaucoma? For years, patients with glaucoma have been prescribed...

Psychedelics and cannabis-focused pharmaceutical company PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) has completed a head-to-head potency comparator study of its two undisclosed DMT-analogue candidates for the treatment of primary open angle glaucoma. What Happened? Following this successful outcome...

The FDA has signed off Sight Sciences Inc's (NASDAQ: SGHT) clinical study to assess investigational higher volume OMNI device to perform canal viscodilation alone to lower intraocular pressure (IOP) in adults with primary open-angle glaucoma (POAG). The PRECISION trial is...

Glaukos Corp (NYSE: GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System. Related Content: William Blair Downgrades Glaukos After Disappointing CMS Rate The iStent infinite is an...

Iridex Corporation (NASDAQ: IRIX) reported Q2 revenue of $13.4 million, the highest since 2007, +116% Y/Y, beating the consensus of $11.61 million. Cyclo G6 product family generated sales of $3.6 million, +70% Y/Y on 16,000 probes sold, up 103% Y/Y. Iridex sold 47 Cyclo G6 Glaucoma Laser...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The beginning of 2021 marked the start of a busy time for cannabinoid biopharmaceutical company Skye Bioscience, Inc. (OTC: SKYE), not the...

Cannabinoid receptors distributed within the body are part of the endocannabinoid system that largely affects processes such as mood, memory, pain-sensation, and appetite, to name a few. Two types of receptors — CB1 and CB2 — “play a vital role in managing different body...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids....

The bullish case for Glaukos Corp (NYSE: GKOS), a company focusing on designing products and procedures for the treatment of glaucoma, is based on expectations the company will stabilize its micro-invasive glaucoma surgery concomitant market share in 2019. But after speaking with dozens of doctors...

Cantor Fitzgerald reiterated its Buy rating and $41 price target on Glaukos Corp (NYSE: GKOS) after the company reported efficacy data from a three-year international study of two iStent devices in over 100 devices. Elaborating on the trial and results, the firm's analyst Elemer Piros noted that...

Shares of Clearside Biomedical Inc (NASDAQ: CLSD) has 91 percent upside, according to a note from Stifel, which initiated coverage of the stock with a Buy rating and $13 price target. "Clearside has developed a novel ocular injection platform to deliver drug[s] optimally throughout the eye by way...

Piper Jaffray said it values Glaukos Corp (NYSE: GKOS)'s suprachoroidal stent in development at $175 million based on Alcon's announcement that it paid $352 million for Glaukos competitor, Transcend, which also has a similar product. Analyst Matt O'Brien said Transcend's CyPass...

Aerie Pharmaceuticals Inc (NASDAQ: AERI) and Aratana Therapeutics Inc (NASDAQ: PETX) have come out with positive announcements that should cheer investors on Thursday. Aerie Pharma reported the successful 12-month interim safety results of Rocket 2, Aerie's second Phase 3 registration trial for...

Glaukos Corp (NYSE: GKOS), a glaucoma medical device maker, hopes to raise $89 million in its upcoming IPO on Thursday. Glaukos will offer 6 million shares between $16 and $17 per share. The company will list on the NYSE under the ticker GKOS. At the midpoint of the offering, Glaukos market cap...